Baird lowered the firm’s price target on Astrana Health (ASTH) to $50 from $86 and keeps an Outperform rating on the shares. The firm said the long-term story remains attractive but the trajectory feels a litle bit different following its Q4 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health’s Earnings Call: Growth Amid Challenges
- Astrana Health price target lowered to $50 from $86 at Baird
- Astrana Health Reports Strong Revenue Growth in 2024
- Buy Recommendation for Astrana Health: Strong Financial Performance and Strategic Positioning Amid Temporary AI-Related Costs
- Astrana Health Delays Yearly Report Filing
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue